Indoco Remedies quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	520	485	+7.3%
EBITDA	46.4	43.1	+7.9%
EBITDA margin	8.9%	8.9%	0.0 pts
Profit before tax	24.2	−13.5	—
Net profit	19.5	−9.2	—
EPS	₹2.11	−₹1.00	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	520	468	476	445	485	438	390	411	433	431	450	459	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	2.0	2.2	−0.0	1.0	0.8	1.6	2.0	0.9	1.6	1.0	2.7	2.4
	522	470	476	446	485	440	392	411	434	433	452	462
	128	105	109	97.9	113	106	85.9	110	94.3	106	122	129
	55.8	39.9	32.5	33.0	38.8	39.2	30.6	34.9	39.2	36.2	27.2	30.6
	−3.6	13.6	−0.7	−10.5	−6.5	−9.8	−10.5	−30.9	3.4	−1.0	−8.1	−17.6
	105	101	109	106	103	107	106	97.6	92.9	97.3	88.3	90.0
	26.9	28.3	45.9	25.6	24.6	26.1	18.0	16.1	17.8	14.3	12.1	10.1
	34.4	34.5	32.5	32.0	32.3	29.7	28.8	28.7	28.8	27.5	26.2	24.4
	189	167	175	187	193	178	179	187	163	145	172	164
	535	489	504	472	498	476	438	443	439	426	439	431
	46.4	41.0	49.7	31.5	43.1	17.5	−0.8	12.0	40.3	47.8	48.9	62.9
	12.0	6.5	17.2	−0.5	10.8	−12.2	−29.6	−16.7	11.4	20.3	22.6	38.6
Profit
	−13.0	−19.6	−28.7	−25.2	−13.0	−36.7	−45.5	−32.0	−4.8	7.0	13.3	30.8
	37.1	97.3	3.7	−6.2	−0.5	0.0	0.0	1.0	0.0	0.0	19.7	−8.2
	24.2	77.7	−25.0	−31.3	−13.5	−36.7	−45.5	−31.0	−4.8	7.0	33.0	22.6
	8.6	10.6	3.0	0.0	0.1	0.0	−2.7	−5.0	3.4	4.8	10.7	2.3
	−3.9	1.7	−4.3	−1.9	−4.4	−0.3	−1.5	2.4	1.8	0.3	0.3	4.8
	4.7	12.3	−1.3	−1.9	−4.3	−0.3	−4.2	−2.6	5.2	5.2	11.0	7.1
	19.5	65.4	−23.7	−29.5	−9.2	−36.4	−41.3	−28.4	−10.0	1.8	22.0	15.6
	19.5	65.4	−23.7	−29.5	−9.2	−36.4	−41.3	−28.4	−10.0	1.8	22.0	15.6
	−0.3	0.7	11.4	−1.3	2.6	−0.2	−2.9	−0.1	−1.0	−0.1	0.8	−0.1
	19.1	66.1	−12.2	−30.7	−6.6	−36.5	−44.3	−28.5	−11.0	1.7	22.9	15.5
	18.4	65.0	−21.6	−29.8	−7.9	−35.8	−40.4	−26.4	−9.6	2.6	22.7	16.3
	1.1	0.5	−2.0	0.3	−1.3	−0.6	−1.0	−2.0	−0.4	−0.8	−0.7	−0.7
Per share
	₹2.11	₹7.09	−₹2.57	−₹3.20	−₹1.00	−₹3.94	−₹4.48	−₹3.08	−₹1.09	₹0.20	₹2.39	₹1.69
	₹2.11	₹7.09	−₹2.56	−₹3.19	−₹1.00	−₹3.94	−₹4.48	−₹3.08	−₹1.08	₹0.20	₹2.39	₹1.69
Other comprehensive income — detail
	−0.3	0.7	11.4	−1.3	2.6	−0.2	−2.9	—	—	—	—	—
	−0.6	−0.6	4.1	−0.8	−0.8	−0.8	−5.1	−0.3	−0.3	−0.3	1.0	−0.3
	−0.2	−0.2	1.0	−0.2	−0.2	−0.2	−1.3	—	—	—	—	—
	—	—	—	—	—	—	—	−0.1	−0.1	−0.1	0.2	−0.1
	0.1	1.2	8.6	−0.5	3.7	0.9	1.0	0.1	−1.0	0.1	0.1	0.1
	0.0	0.0	0.2	0.2	0.5	0.5	0.1	—	—	—	—	—
	—	—	—	—	—	—	—	0.0	−0.2	0.0	0.0	0.0
	18.0	65.7	−10.2	−31.1	−5.4	−36.0	−43.3	−26.5	−10.6	2.5	23.5	16.2
	1.1	0.5	−2.0	0.3	−1.3	−0.6	−1.0	−2.0	−0.4	−0.8	−0.7	−0.7
Per share — as-filed variants
	₹2.11	₹7.09	−₹2.57	−₹3.20	−₹1.00	−₹3.94	−₹4.48	−₹3.08	−₹1.09	₹0.20	₹2.39	₹1.69
	₹2.11	₹7.09	−₹2.56	−₹3.19	−₹1.00	−₹3.94	−₹4.48	−₹3.08	−₹1.08	₹0.20	₹2.39	₹1.69
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	340	309	335	325	339	303	284	297	296	290	309	317
	65.4%	66.2%	70.4%	73.0%	70.0%	69.2%	72.8%	72.3%	68.4%	67.2%	68.7%	69.0%
Adjusted (ex-exceptional items) — derived
	−13.0	−19.6	−28.7	−25.2	−13.0	−36.7	−45.5	−32.0	−4.8	7.0	13.3	30.8
	37.1	97.3	3.7	−6.2	−0.5	0.0	0.0	1.0	0.0	0.0	19.7	−8.2
	−10.4	−16.5	−27.2	−23.7	−8.8	−36.4	−41.3	−29.3	−10.0	1.8	8.9	21.2
	−₹1.13	−₹1.79	−₹2.95	−₹2.57	−₹0.96	−₹3.94	−₹4.48	−₹3.18	−₹1.09	₹0.20	₹0.96	₹2.30

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDOCO₹213.75

Indoco Remedies Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSAIPARENT PANACEABIO HIKAL WINDLAS HESTERBIO DCAL SYNCOMF SOLARAMcap ₹1,973 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	459.4	449.6	431.5	432.7	410.6	390.2	437.9	484.7	445.4	475.6	467.5	520.2
Other Income	2.4	2.7	1.0	1.6	0.9	2.0	1.6	0.8	1.0	-0.0	2.2	2.0
Total Income	461.8	452.3	432.5	434.2	411.4	392.2	439.5	485.4	446.3	475.6	469.7	522.1
Expenses
+ Cost of Materials Consumed	129.3	121.8	106.2	94.3	109.9	85.9	105.5	113.0	97.9	109.2	104.6	127.6
+ Purchases of Stock-in-Trade	30.6	27.2	36.2	39.2	34.9	30.6	39.2	38.8	33.0	32.5	39.9	55.8
+ Changes in Inventories	-17.6	-8.1	-1.0	3.4	-30.9	-10.5	-9.8	-6.5	-10.5	-0.7	13.6	-3.6
+ Employee Benefit Expense	90.0	88.3	97.3	92.9	97.6	106.4	107.0	103.2	106.0	109.4	101.4	105.1
+ Finance Costs	10.1	12.1	14.3	17.8	16.1	18.0	26.1	24.6	25.6	45.9	28.3	26.9
+ Depreciation & Amortisation	24.4	26.2	27.5	28.8	28.7	28.8	29.7	32.3	32.0	32.5	34.5	34.4
+ Other Expenses	164.2	171.6	145.0	162.7	187.1	178.7	178.4	193.1	187.4	175.5	167.0	188.8
Total Expenses	430.9	439.1	425.6	439.1	443.4	437.8	476.2	498.4	471.5	504.3	489.3	535.1
EBITDA	62.9	48.9	47.8	40.3	12.0	-0.8	17.5	43.1	31.5	49.7	41.0	46.4
EBIT	38.6	22.6	20.3	11.4	-16.7	-29.6	-12.2	10.8	-0.5	17.2	6.5	12.0
Profit
PBT before Exceptional Items	30.8	13.3	7.0	-4.8	-32.0	-45.5	-36.7	-13.0	-25.2	-28.7	-19.6	-13.0
+ Exceptional Items	-8.2	19.7	0.0	0.0	1.0	0.0	0.0	-0.5	-6.2	3.7	97.3	37.1
Pretax Income	22.6	33.0	7.0	-4.8	-31.0	-45.5	-36.7	-13.5	-31.3	-25.0	77.7	24.2
+ Current Tax	2.3	10.7	4.8	3.4	-5.0	-2.7	0.0	0.1	0.0	3.0	10.6	8.6
+ Deferred Tax	4.8	0.3	0.3	1.8	2.4	-1.5	-0.3	-4.4	-1.9	-4.3	1.7	-3.9
Tax Expense	7.1	11.0	5.2	5.2	-2.6	-4.2	-0.3	-4.3	-1.9	-1.3	12.3	4.7
Net Income	15.6	22.0	1.8	-10.0	-28.4	-41.3	-36.4	-9.2	-29.5	-23.7	65.4	19.5
+ Net Income — Continuing Ops	15.6	22.0	1.8	-10.0	-28.4	-41.3	-36.4	-9.2	-29.5	-23.7	65.4	19.5
+ Other Comprehensive Income	-0.1	0.8	-0.1	-1.0	-0.1	-2.9	-0.2	2.6	-1.3	11.4	0.7	-0.3
Total Comprehensive Income	15.5	22.9	1.7	-11.0	-28.5	-44.3	-36.5	-6.6	-30.7	-12.2	66.1	19.1
Net Income to Common	16.3	22.7	2.6	-9.6	-26.4	-40.4	-35.8	-7.9	-29.8	-21.6	65.0	18.4
Minority Interest	-0.7	-0.7	-0.8	-0.4	-2.0	-1.0	-0.6	-1.3	0.3	-2.0	0.5	1.1
Per Share
Basic EPS	1.69	2.39	0.20	-1.09	-3.08	-4.48	-3.94	-1.00	-3.20	-2.57	7.09	2.11
Diluted EPS	1.69	2.39	0.20	-1.08	-3.08	-4.48	-3.94	-1.00	-3.19	-2.56	7.09	2.11
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-2.9	-0.2	2.6	-1.3	11.4	0.7	-0.3
+ Items NOT to be Reclassified to P&L	-0.3	1.0	-0.3	-0.3	-0.3	-5.1	-0.8	-0.8	-0.8	4.1	-0.6	-0.6
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-1.3	-0.2	-0.2	-0.2	1.0	-0.2	-0.2
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	0.2	-0.1	-0.1	-0.1	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	0.1	0.1	0.1	-1.0	0.1	1.0	0.9	3.7	-0.5	8.6	1.2	0.1
+ Tax on Items to be Reclassified	—	—	—	—	—	0.1	0.5	0.5	0.2	0.2	0.0	0.0
+ Tax on Items to be Reclassified — alt tag	0.0	0.0	0.0	-0.2	0.0	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	16.2	23.5	2.5	-10.6	-26.5	-43.3	-36.0	-5.4	-31.1	-10.2	65.7	18.0
Comprehensive Income — Non-controlling Interests	-0.7	-0.7	-0.8	-0.4	-2.0	-1.0	-0.6	-1.3	0.3	-2.0	0.5	1.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	1.69	2.39	0.20	-1.09	-3.08	-4.48	-3.94	-1.00	-3.20	-2.57	7.09	2.11
Diluted EPS — Continuing Operations	1.69	2.39	0.20	-1.08	-3.08	-4.48	-3.94	-1.00	-3.19	-2.56	7.09	2.11
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	317.1	308.8	290.0	295.9	296.6	284.2	302.9	339.3	324.9	334.6	309.5	340.3
Gross Margin %	69.02	68.67	67.21	68.38	72.25	72.84	69.18	70.01	72.96	70.35	66.19	65.43
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	30.8	13.3	7.0	-4.8	-32.0	-45.5	-36.7	-13.0	-25.2	-28.7	-19.6	-13.0
− Exceptional Items (reconciliation)	-8.2	19.7	0.0	0.0	1.0	0.0	0.0	-0.5	-6.2	3.7	97.3	37.1
Net Income Adj (tax-effected)	21.2	8.9	1.8	-10.0	-29.3	-41.3	-36.4	-8.8	-23.7	-27.2	-16.5	-10.4
EPS Adj	2.30	0.96	0.20	-1.09	-3.18	-4.48	-3.94	-0.96	-2.57	-2.95	-1.79	-1.13
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	18.4	18.4	18.4	18.4	18.4	18.5	18.5	18.5	18.5	18.5	18.5	18.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Indoco Remedies Q2 FY27 results (July–September 2026)

Filed with NSE on Tuesday, 27 October 2026 at 12:47 pm IST

Indoco Remedies (NSE: INDOCO) reported its Q2 FY27 results (July–September 2026) on Tuesday, 27 October 2026 at 12:47 pm IST. Consolidated net profit attributable to shareholders was ₹18.4 crore, against a loss of ₹7.9 crore in Q2 FY26 and down 71.7% from ₹65 crore in Q1 FY27. Revenue from operations was ₹520 crore, up 7.3% year on year and up 11.3% from the previous quarter.

Q2 FY26 results (a year earlier): 6 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit (shareholders'): ₹18.4 Crloss ₹7.9 Cr in Q2 FY26−71.7% vs Q1 FY27Total incl. minority interest ₹19.5 Cr
Revenue from operations: ₹520 Cr+7.3% vs Q2 FY26+11.3% vs Q1 FY27
Operating margin (EBIT): 2.3%+0.1 pts vs Q2 FY26+0.9 pts vs Q1 FY27EBIT ₹12 Cr
EBITDA: ₹46.4 Cr+7.9% vs Q2 FY26+13.2% vs Q1 FY27margin 8.9%
Earnings per share (basic): ₹2.11−70.2% vs Q1 FY27
Net profit margin: 3.5%+5.2 pts vs Q2 FY26−10.4 pts vs Q1 FY27

Questions

What was Indoco Remedies' net profit in Q2 FY27?

Consolidated net profit attributable to shareholders was ₹18.4 crore, against a loss of ₹7.9 crore in Q2 FY26 and down 71.7% from ₹65 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹19.5 crore.

How were Indoco Remedies' Q2 FY27 results?

A net profit of ₹18.4 crore, against a loss of ₹7.9 crore in Q2 FY26. Revenue was up 7.3% at ₹520 crore. The operating margin was 2.3%, up 0.1 percentage points from 2.2% a year earlier. Against Q1 FY27, net profit was down 71.7% and revenue up 11.3%.

What was Indoco Remedies' net profit in the first half of FY27?

Consolidated net profit attributable to shareholders for the first half of FY27 (April–September 2026) was ₹83.4 crore, against a loss of ₹43.7 crore in the same months a year earlier. Revenue from operations was ₹988 crore, up 7.1%.

What was Indoco Remedies' revenue in Q2 FY27?

Revenue from operations was ₹520 crore, up 7.3% year on year and up 11.3% from the previous quarter.

What was Indoco Remedies' EPS in Q2 FY27?

Basic earnings per share were ₹2.11.

What was Indoco Remedies' revenue in FY26?

Revenue from operations was ₹1,845 crore in FY26 (April 2025–March 2026), up 10.8% from ₹1,665 crore in FY25. It was ₹1,817 crore in FY24 and ₹1,669 crore in FY23: up 10.6% over three years, 3.4% a year on average.

What was Indoco Remedies' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹12 crore, a margin of 2.3%, against 1.4% in Q1 FY27 and 2.2% in Q2 FY26. EBITDA was ₹46.4 crore, 8.9% of revenue.

What is Indoco Remedies' net profit margin?

Indoco Remedies' net profit margin was 3.5% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations), against −1.6% in Q2 FY26 (up 5.2 percentage points). For FY26 as a whole it was −5.2%.

What was Indoco Remedies' net profit in FY26?

Consolidated net profit attributable to shareholders was a loss of ₹95.2 crore in FY26 (April 2025–March 2026), wider than the loss of ₹73.7 crore in FY25. It was a profit of ₹98.5 crore in FY24 and a profit of ₹142 crore in FY23.

How has Indoco Remedies' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: a loss of ₹29.8 crore in Q3 FY26, a loss of ₹21.6 crore in Q4 FY26, a profit of ₹65 crore in Q1 FY27 and a profit of ₹18.4 crore in Q2 FY27. That is a combined profit of ₹31.9 crore over the four quarters. Revenue from operations: ₹445 crore, ₹476 crore, ₹468 crore and ₹520 crore.

When did Indoco Remedies announce its Q2 FY27 results?

On Tuesday, 27 October 2026 at 12:47 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 6 November 2025.

When will Indoco Remedies announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Indoco Remedies figures come from?

From Indoco Remedies' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 27 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.